Hls Therapeutics Stock Performance
| HLS Stock | CAD 3.96 0.04 1.00% |
On a scale of 0 to 100, HLS Therapeutics holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 0.32, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, HLS Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding HLS Therapeutics is expected to be smaller as well. Please check HLS Therapeutics' semi variance, and the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether HLS Therapeutics' current trending patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in HLS Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, HLS Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
Last Split Factor 1:5 | Dividend Date 2023-06-15 | Ex Dividend Date 2023-04-27 | Last Split Date 2006-10-26 |
1 | HLS Therapeutics to Announce Q3 2024 Financial Results - TipRanks | 10/24/2024 |
2 | HLS Therapeutics Third Quarter 2024 Earnings Misses Expectations - Yahoo Finance | 11/08/2024 |
| Begin Period Cash Flow | 20.7 M |
HLS |
HLS Therapeutics Relative Risk vs. Return Landscape
If you would invest 360.00 in HLS Therapeutics on October 7, 2024 and sell it today you would earn a total of 36.00 from holding HLS Therapeutics or generate 10.0% return on investment over 90 days. HLS Therapeutics is generating 0.1973% of daily returns assuming 2.9879% volatility of returns over the 90 days investment horizon. Simply put, 26% of all stocks have less volatile historical return distribution than HLS Therapeutics, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
HLS Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HLS Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as HLS Therapeutics, and traders can use it to determine the average amount a HLS Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.066
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HLS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.99 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.2 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average HLS Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HLS Therapeutics by adding it to a well-diversified portfolio.
HLS Therapeutics Fundamentals Growth
HLS Stock prices reflect investors' perceptions of the future prospects and financial health of HLS Therapeutics, and HLS Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HLS Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0274 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | 199.48 M | ||||
| Shares Outstanding | 31.79 M | ||||
| Price To Book | 1.10 X | ||||
| Price To Sales | 2.21 X | ||||
| Revenue | 63.07 M | ||||
| Gross Profit | 50.76 M | ||||
| EBITDA | 21.94 M | ||||
| Net Income | (27.53 M) | ||||
| Cash And Equivalents | 20.72 M | ||||
| Cash Per Share | 1.70 X | ||||
| Total Debt | 87.62 M | ||||
| Debt To Equity | 50.50 % | ||||
| Current Ratio | 1.70 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | 15.79 M | ||||
| Earnings Per Share | (0.99) X | ||||
| Market Capitalization | 125.9 M | ||||
| Total Asset | 209.06 M | ||||
| Retained Earnings | (175.46 M) | ||||
| Working Capital | 17.41 M | ||||
About HLS Therapeutics Performance
By examining HLS Therapeutics' fundamental ratios, stakeholders can obtain critical insights into HLS Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that HLS Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 410.80 | 431.34 | |
| Return On Tangible Assets | (0.68) | (0.64) | |
| Return On Capital Employed | (0.07) | (0.06) | |
| Return On Assets | (0.15) | (0.14) | |
| Return On Equity | (0.32) | (0.31) |
Things to note about HLS Therapeutics performance evaluation
Checking the ongoing alerts about HLS Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HLS Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HLS Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 63.07 M. Net Loss for the year was (27.53 M) with profit before overhead, payroll, taxes, and interest of 50.76 M. | |
| About 65.0% of the company shares are owned by institutional investors |
- Analyzing HLS Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HLS Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining HLS Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HLS Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of HLS Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HLS Therapeutics' stock. These opinions can provide insight into HLS Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.